Last €2.29 EUR
Change Today +0.065 / 2.92%
Volume 675.0
WL6 On Other Exchanges
As of 11:38 AM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

wilex ag (WL6) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/18/13 - €7.28
52 Week Low
02/10/14 - €1.89
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for WILEX AG (WL6)

Related News

No related news articles were found.

wilex ag (WL6) Related Businessweek News

No Related Businessweek News Found

wilex ag (WL6) Details

WILEX AG, a biopharmaceutical company, is focuses on the research, development, manufacture, approval, and marketing of drugs and diagnostic agents in the field of oncology. The company operates in three segments: Therapeutics (Rx), Diagnostics (Dx), and Customer Specific Research (Cx). Its primary product candidates based on antibodies and small-molecule compounds comprise REDECTANE, an imaging diagnostic candidate that has completed Phase III clinical trials for the treatment of renal masses; and MESUPRON, which has completed Phase clinical trials for the treatment of pancreatic and breast cancer. The company also provides customer specific contract services related to a technology platform for therapeutic antibody drug conjugates; and preclinical research services in the field of cancer, as well as inflammatory and autoimmune diseases. WILEX AG has a strategic alliance with UCB Pharma S.A. (UCB) to develop UCB’s preclinical oncological portfolio comprising two small-molecule programs and three antibody programs. The company was formerly known as WILEX Biotechnology GmbH and changed its name to WILEX AG in February 2001. WILEX AG was founded in 1997 and is headquartered in Munich, Germany.

61 Employees
Last Reported Date: 07/16/14
Founded in 1997

wilex ag (WL6) Top Compensated Officers

Chief Financial Officer and Member of the Exe...
Total Annual Compensation: €287.2K
Head of Research & Development and Member of ...
Total Annual Compensation: €245.8K
Compensation as of Fiscal Year 2013.

wilex ag (WL6) Key Developments

Wilex AG, H1 2014 Earnings Call, Jul 15, 2014

Wilex AG, H1 2014 Earnings Call, Jul 15, 2014

Wilex AG Reports Consolidated Earnings Results for the Six Months Ended May 31, 2014

Wilex AG reported consolidated earnings results for the six months ended May 31, 2014. For the period, the company reported sales revenue of EUR 1.189 million against EUR 6.595 million a year ago. Operating loss was EUR 4.310 million against EUR 3.490 million a year ago. Loss before tax was EUR 4.344 million against EUR 3.540 million a year ago. Net loss for the year was EUR 4.391 million against EUR 3.540 million a year ago. Loss per share was EUR 0.14 against EUR 0.11 a year ago. Cash flow from operating activities was EUR 6.017 million against EUR 10.504 million a year ago. Net loss is attributable to lower sales revenue and income.

Wilex AG and RedHill Biopharma Ltd. Enter into an Exclusive License Agreement for Mesupron

Wilex AG and RedHill Biopharma Ltd. announced that they have signed an exclusive license agreement for the oncology drug candidate MESUPRON(R). The small molecule is a proprietary, first-in-class urokinase-type plasminogen activator (uPA) inhibitor administered by oral capsule. WILEX has completed several clinical studies with MESUPRON(R) in different indications, including two Phase II proof of concept studies for pancreatic cancer and metastatic breast cancer. Under the terms of the agreement, RedHill acquired the exclusive development and commercialization rights to MESUPRON(R) outside China, Hong Kong, Taiwan and Macao for all indications. RedHill will pay WILEX an upfront payment of USD 1 million and potential tiered royalties on net revenues, ranging from mid-teens up to 30%. RedHill will be responsible for development, regulatory and commercialization of MESUPRON(R).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WL6:GR €2.29 EUR +0.065

WL6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WL6.
View Industry Companies

Industry Analysis


Industry Average

Valuation WL6 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.1x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WILEX AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at